Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04322708 · ClinicalTrials.gov registry record · Phase 2
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis
A Phase 2 study, sponsored by Allakos.
- Completed
- Registry status
- Phase 2
- Development phase
- 277
- Enrollment target
NCT04322708: Completed Phase 2 study, sponsored by Allakos.
NCT04322708 is a Phase 2 study that has completed, run by Allakos. The registered enrollment target is 277 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (108% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04322708, a Phase 2 study, has completed, sponsored by Allakos.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 277 participants
- Enrollment target
Study Summary
This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic esophagitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.
Primary Outcome
Esophageal intraepithelial eosinophil count obtained by esophageal endoscopy with biopsies.
Interventions
- OTHER Placebo
- DRUG lirentelimab (AK002)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2020-07-06 |
| Est. Completion | 2022-01-18 |
| Phase | Phase 2 |
What the finished NCT04322708 record still lists
NCT04322708 is an interventional study that assigns participants to a tested intervention. The registered 277 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (108% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04322708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04322708 about?
NCT04322708 is a clinical study titled "A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis". This is a Phase 2/3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult and adolescent patients with active eosinophilic esophagitis. Subjects who complete the randomized, double-blind, placebo...
What is the current status of trial NCT04322708?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 277 participants. The study started on 2020-07-06. Estimated completion is 2022-01-18.
What interventions are being tested in trial NCT04322708?
The interventions under investigation include: Placebo (OTHER), lirentelimab (AK002) (DRUG).
Who is sponsoring clinical trial NCT04322708?
This trial is sponsored by Allakos, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04322708's enrollment target sits among peer trials
277 202nd of 2000 higher than 1,799 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05818683 · 277 participants · Phase 1
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
- NCT06789913 · 277 participants · Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI